ArticleJournal of gastrointestinal cancer2017
Validation of a Liver Index and Its Significance for HCC Aggressiveness.
Article in Journal of gastrointestinal cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Combined treatment with vitamin K2 and albumin inhibits growth in hepatocellular carcinoma cells by promoting differentiation and apoptosis.Molecular biology reports · 2026Article
- Impact of Serum Albumin Levels on Prognosis and Recurrence in Patients with Hepatocellular Carcinoma.Cancers · 2025Article
- The Red Cell Distribution Width to Albumin Ratio: A Novel Prognostic Indicator in Hepatitis B Virus-Related Hepatocellular Carcinoma.International journal of medical sciences · 2025Article
- RAR-Based Prognostic Model for Predicting Overall Survival in Hepatitis B Virus-Related Hepatocellular Carcinoma: A Multicenter Study.Journal of inflammation research · 2025Article
- Discordance among aggressiveness characteristics of hepatocellular carcinoma: Portal vein thrombosis and multifocality, related to tumor size, but not to serum alpha-fetoprotein level.Liver research (Beijing, China) · 2023Article
- Serum Levels of Netrin-4 and Its Association With Hepatocellular Carcinoma: Results From a Case-Control Study.Cureus · 2023Article
- Molecular mechanism of albumin in suppressing invasion and metastasis of hepatocellular carcinoma.Liver international : official journal of the International Association for the Study of the Liver · 2022Article
- Microscopic Portal Vein Invasion in Relation to Tumor Focality and Dimension in Patients with Hepatocellular Carcinoma.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2022Article
- Circular RNA hsa_circ_0004277 Stimulates Malignant Phenotype of Hepatocellular Carcinoma and Epithelial-Mesenchymal Transition of Peripheral Cells.Frontiers in cell and developmental biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe recently constructed a liver index (LI) from four liver parameters, namely: blood total bilirubin, gamma glutamyl transpeptidase (GGTP), albumin, and platelet levels (a cirrhosis surrogate). We found that the scores for the liver index related significantly to a four-parameter HCC aggressiveness index (maximum tumor diameter, multifocality, percent portal vein invasion, and blood AFP levels).
aimsTo validate the relationship of liver parameters to tumor aggressiveness parameters in a larger, different HCC dataset.
resultsWe now confirm these associations in another large HCC cohort. Furthermore, this liver index showed significant trends with the individual HCC aggressiveness parameters.
conclusionsThese results provide further support for the idea that liver microenvironment, as reflected in liver function tests, may relate to HCC behavior.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.